182 filings
Page 5 of 10
424B5
idpccj8r 5x
19 Jul 22
Prospectus supplement for primary offering
8:09pm
6-K
g0u01uh
17 Jun 22
Current report (foreign)
6:05am
6-K
ty1dbcez8 z9
27 May 22
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
6:05am
6-K
tj648
10 May 22
Addex Shareholders Approve All Resolutions at Annual General Meeting
6:05am
6-K
p91qh0clbh ig6
5 May 22
Current report (foreign)
6:03am
EFFECT
lbisgnwzg1rywv69
20 Apr 22
Notice of effectiveness
12:15am
6-K
5nzvtctwwl96tqr3p1k
13 Apr 22
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
6:05am
6-K
229v1oauopilsf9asyc2
6 Apr 22
Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
6:05am
EFFECT
6oikd zig2dxy
5 Apr 22
Notice of effectiveness
12:15am
POS AM
t5ow5wcfenvzugb4m0
31 Mar 22
Prospectus update (post-effective amendment)
4:10pm
6-K
dyyamq1r8engsooh9
31 Mar 22
Addex Convenes Annual General Meeting 2022
6:05am
POS AM
ji7ka4uyim 2h4ix
29 Mar 22
Prospectus update (post-effective amendment)
7:30am
CORRESP
vrw7lny5
29 Mar 22
Correspondence with SEC
12:00am
6-K
l9qe4z24qvz
10 Mar 22
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update
6:05am
6-K
ano85
3 Feb 22
Addex Increases Issued Share Capital to Create Treasury Shares
6:05am
EFFECT
fam08tt 2fc9pwsp2ebo
19 Jan 22
Notice of effectiveness
12:15am
424B3
lnhmch22u 85x
19 Jan 22
Prospectus supplement
12:00am
UPLOAD
g2i0g
14 Jan 22
Letter from SEC
12:00am
CORRESP
14ivvakm 41iy4
14 Jan 22
Correspondence with SEC
12:00am